Key result
Second-line nilotinib was associated with a significantly higher frequency of overt peripheral arterial occlusive disease compared to first-line nilotinib (3 vs 0 patients; p<0.001).
Why the study?
Does nilotinib treatment increase the risk of peripheral arterial occlusive disease in patients with chronic phase chronic myeloid leukemia?
Cohort (n=88)
Does nilotinib treatment increase the risk of peripheral arterial occlusive disease in patients with chronic phase chronic myeloid leukemia?
p-value: p=<0.001
Long-term nilotinib treatment, particularly when used as second-line therapy, is associated with the emergence of peripheral arterial occlusive disease in patients with chronic myeloid leukemia, warranting routine vascular assessment.
May warrant vascular monitoring with second-line nilotinib; leaves open causality and need for randomized confirmation.
Introduction ENESTnd trial, nilotinib showed superior efficacy and good tolerability compared with standard dose of imatinib in chronic phase chronic myeloid leukemia (CP CML). However, serious vascular adverse events such as ischemic heart disease (IHD) and peripheral arterial occlusive disease (PAOD) have been reported. Therefore, we have prospectively evaluated for emergence of PAOD in all (CML patients treated with nilotinib. Materials and methods Between May 2005 and April 2013, a total of 98 CP CML patients on nilotinib treatment were tested with laboratory studies, electrocardiography and ankle brachial index (ABI) + pulse wave velocity (PWV). Abnormal ABI index was defined with below 1.0 and abnormal PWV as over 1200∼2000 cm/sec adjusted by age. and patients who had abnormal ABI or PWV were performed with computed tomography angiography. Results So far, 88 of total 98 patients (57 male) were evaluated with screening test. 17 patients of 88 showed abnormal ABI or PWV. Finally, 3 patients (3.4%) of 17 were diagnosed with overt PAOD by CT angiography (2 upper extremity, 1 lower extremity). The median age was 46 year old (range, 19∼72). The median duration of disease was 49 months (range,1.2 ∼ 65) and 51.3 months (range,36 ∼ 115) in the patients treated with first-line and second-line nilotinib, respectively. The median mean daily dosage of nilotinib was 710mg (range, 656∼800mg) and 737 mg (range, 500∼800mg) in each group. The duration of nilotinib treatment was 46.3 months (range, 0.7∼64.2) and 25.0 months (range, 2.8∼55.8) in each group. Comparing first and second-line nilotinib treated patients, an abnormal ABI or PWV (1 versus 16 patients) and overt PAOD (0 versus 3 patients) was more frequent in patients with second-line nilotinib (p=0.042, p< 0.001, p<0.001). Conclusion Our preliminary data suggest an importance of PAOD evaluation in patients with long-term nilotinib treatment (p=0.042) and a routine assessment of PAOD including ischemic heart disease (IHD) is strongly recommended on regular basis. Disclosures: No relevant conflicts of interest to declare.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2013) conducted a cohort in Chronic phase chronic myeloid leukemia (CP CML) (n=88). Second-line nilotinib vs. First-line nilotinib was evaluated on Overt peripheral arterial occlusive disease (PAOD) (p=<0.001). Second-line nilotinib was associated with a significantly higher frequency of overt peripheral arterial occlusive disease compared to first-line nilotinib (3 vs 0 patients; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: